UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/671,859	09/26/2003	Michael E. O'Donnell	22221/1120 (RU 339)	8720
Nixon Peabody	7590 12/04/200 LLP	EXAMINER		
Clinton Square		HUTSON, RICHARD G		
P.O. Box 31051 Rochester, NY 14603-1051			ART UNIT	PAPER NUMBER
			1652	
			MAIL DATE	DELIVERY MODE
			12/04/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/671,859	O'DONNELL ET AL.			
Office Action Summary	Examiner	Art Unit			
	Richard G. Hutson	1652			
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on 21 Au	ugust 2008				
	action is non-final.				
·=					
closed in accordance with the practice under E	•				
Disposition of Claims					
4)⊠ Claim(s) <u>17-21</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>17-21</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	r election requirement.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau					
* See the attached detailed Office action for a list	of the certified copies not receive	d.			
Attachment(s)	л П	(DTO 440)			
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)				
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P				
Paper No(s)/Mail Date	6)				

DETAILED ACTION

Applicant's cancellation of claims 1, 2, 7-15, in the paper of 8/21/2008, is acknowledged. Claims 17-21 are at issue and are present for examination. Applicants' arguments filed on 8/21/2008, have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Upon further consideration, it has come to the attention of the examiner that the following rejections are appropriate and thus this action is non-final. Any inconvenience to applicants is regretted.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 17-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Kaboev et al. (J. Bacteriology, Vol 145, No. 1, pp 21-26 1981).

Kaboev et al. teach the purification and properties of DNA polymerase I from Bacillus stearothermophilus (See table I and supporting text). Kaboev et al. teach that the DNA polymerase I that they isolated has some differences from that isolated by others and this leads Kaboev et al. to hypothesize that their DNA polymerase I preparation is not homogeneous and is contaminated with other DNA polymerase activities. Based upon this it is the position of the office that the *Bacillus* stearothermophilus extract taught by Koboev et al. contains the delta subunit of the DNA polymerase III holoenzyme as well as a clamp loader and DNA polymerase III complex comprising said subunit and the amino acid sequence of SEQ ID NO: 178 of the delta subunit of DNA polymerase III of *Bacillus stearothermophilus* is a feature that is inherent to the subunit. Thus this crude extract taught by Kaboev et al. anticipates claims 16-20 drawn to an isolated delta subunit comprising the amino acid sequence of SEQ ID NO: 178 and a DNA polymerase III holoenzyme and clamp loader complex comprising this subunit.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 17-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Janjic et al. (U.S. Patent No. 6,677,146 B1 issued 1/13/2004) and Kaboev et al. (J. Bacteriology, Vol 145, No. 1, pp 21-26 1981).

Janjic et al. teach the gene encoding and amino acid sequences of DNA

Polymerase III holoenzyme subunits from a number of thermophilic organisms. In

Art Unit: 1652

particular Janjic et al. teach the DNA polymerase III holoenzyme subunit and accessory proteins of *T. thermophilus* as well as antibodies, primers, probes and other reagents useful to identify DNA polymerase III molecules. Janjic et al. specifically teach the cloning and expression of the holA gene encoding the δ-subunit of DNA polymerase III holoenzyme from *E. coli, B. subtilis, A. aeolicus* and *T. thermophilus*, as well as a consensus sequence between each of these delta subunits.

As discussed above, Kaboev et al. teach the purification and properties of DNA polymerase I from *Bacillus stearothermophilus*. Kaboev et al. teach that the DNA polymerase I that they isolated has some differences from that isolated by others and lead Kaboev et al. to hypothesize that their DNA polymerase I preparation is not homogeneous and is contaminated with other DNA polymerase activities.

One of skill in the art at the time of filing would have been motivated to isolate the delta subunit of the DNA polymerase III holoenzyme of *Bacillus stearothermophilus* using the polyclonal antibodies of Janjic et al. and the *Bacillus stearothermophilus* cell extract of Kobev et al. The motivation to isolate this subunit is to identify those DNA polymerase activities found in the preparation of Kobev et al. The expectation of success is high based upon the high degree of skill in the art with respect to protein purification and the results of both Janjic et al. who successfully isolate the delta subunit of DNA polymerase III from *T. thermophilus* and the results of Kaboev et al. who suggest that polymerase activities in addition to DNA polymerase I exist in their DNA polymerase preparations.

Application/Control Number: 10/671,859

Art Unit: 1652

It is noted that the amino acid sequence of SEQ ID NO: 178 of the delta subunit of DNA polymerase III of *Bacillus stearothermophilus* is a feature that is inherent to the subunit. It would have been obvious to put the isolated beta subunit in some sort of container that would have also inherently had some residual dNTPs, thus meeting the limitation of claim 21. Further the delta prime and tau subunits comprising the clamp loader would have inherently had the amino acid sequences of SEQ ID NO: 180 and 182, respectively. Thus claims 17-21 are obvious over Janjic et al. (U.S. Patent No. 6,677,146 B1 issued 1/13/2004) and Kaboev et al. (J. Bacteriology, Vol 145, No. 1, pp 21-26 1981).

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Hutson whose telephone number is 571-272-0930. The examiner can normally be reached on M-F, 7:00-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nashaat T. Nashed can be reached on 571-272-0934. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/671,859 Page 6

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

rgh 11/14/2008

/Richard G Hutson/ Primary Examiner, Art Unit 1652